Back to Search
Start Over
PAX4 gene delivery improves β-cell function in human islets of Type II diabetes.
- Source :
- Regenerative Medicine; 2024, Vol. 19 Issue 5, p239-246, 7p
- Publication Year :
- 2024
-
Abstract
- Aim: Type II diabetes (T2D) stems from insulin resistance, with β-cell dysfunction as a hallmark in its progression. Studies reveal that β cells undergo apoptosis or dedifferentiation during T2D development. The transcription factor PAX4 is vital for β differentiation and survival, thus may be a potential enhancer of β-cell function in T2D islets. Materials & methods: Human PAX4 cDNA was delivered into T2D human islets with an adenoviral vector, and its effects on β cells were examined. Results: PAX4 gene delivery significantly improved β-cell survival, and increased β-cell composition in the T2D human islets. Basal insulin and glucose-stimulated insulin secretion in PAX4-expressing islets were substantially higher than untreated or control-treated T2D human islets. Conclusion: Introduced PAX4 expression in T2D human islets improves β-cell function, thus could provide therapeutic benefits for T2D treatment. Type II diabetes (T2D) results from insulin resistance, with β-cell dysfunction playing a pivotal role in its progression. Deficits in β-cell mass and function have been attributed primarily to β-cell death through apoptosis; however, recent studies suggest β-cell failure can also arise from β-cell dedifferentiation – that is, β cells undergo a loss of mature identity, adopting either progenitor-like or glucagon-producing α cell states during T2D development. Therefore, a strategy preventing β-cell dedifferentiation while promoting its survival is beneficial for T2D treatment. In this study, we explored whether PAX4, a critical transcription factor for β differentiation and survival, could alleviate β-cell dysfunction in human islets derived from T2D patients. To accomplish that, human PAX4 cDNA was delivered into human islets isolated from T2D donors by an adenoviral vector-based vector, Ad5.Pax4 and its effects on β-cell function were evaluated. The results showed PAX4 expression significantly improved β-cell survival and increased β-cell composition in the T2D islets. Notably, PAX4-treated T2D islets exhibited significantly higher basal insulin secretion and glucose-stimulated insulin secretion than control-treated islets. The data demonstrate that PAX4 gene delivery into T2D human islets enhances β-cell mass and function, and thus may offer therapeutic benefits in the treatment of T2D. Article highlights Type II diabetes (T2D) arises from insulin resistance, with β-cell dysfunction as a hallmark in its progression, underscoring the need for therapies that enhance β-cell function. The transcription factor PAX4 plays critical roles in β differentiation and survival, making it a potential enhancer of β-cell function in T2D human islets. PAX4 gene delivery mediated by an adenoviral vector, Ad5.Pax4, increases the composition of β cells, enhances their survival, and improves their function in T2D human islets. PAX4 gene delivery may offer therapeutic benefits for T2D treatment by restoring β-cell function through Pax4's effects on β differentiation and survival, thereby improving glucose homeostasis and overall disease management. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17460751
- Volume :
- 19
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Regenerative Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 178944371
- Full Text :
- https://doi.org/10.1080/17460751.2024.2343538